
Michael G Head

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7750153/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	UK investments in global infectious disease research 1997–2010: a case study. Lancet Infectious Diseases, The, 2013, 13, 55-64.	9.1	105
2	Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes. Lancet Infectious Diseases, The, 2018, 18, 894-902.	9.1	100
3	Ebola research funding: a systematic analysis, 1997–2015. Journal of Global Health, 2016, 6, 020703.	2.7	62
4	Perceived COVID-19 vaccine effectiveness, acceptance, and drivers of vaccination decision-making among the general adult population: A global survey of 20 countries. PLoS Neglected Tropical Diseases, 2022, 16, e0010103.	3.0	53
5	Differences in research funding for women scientists: a systematic comparison of UK investments in global infectious disease research during 1997–2010. BMJ Open, 2013, 3, e003362.	1.9	50
6	Global funding trends for malaria research in sub-Saharan Africa: a systematic analysis. The Lancet Global Health, 2017, 5, e772-e781.	6.3	39
7	The allocation of US\$105 billion in global funding from G20 countries for infectious disease research between 2000 and 2017: a content analysis of investments. The Lancet Global Health, 2020, 8, e1295-e1304.	6.3	34
8	Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997–2013. EBioMedicine, 2016, 3, 180-190.	6.1	28
9	Pneumococcal conjugate vaccine implementation in middle-income countries. Pneumonia (Nathan Qld) Tj ETQq	1 1.0,7843 6.1	14 rgBT /Ove
10	Malaria in China, 2011–2015: an observational study. Bulletin of the World Health Organization, 2017, 95, 564-573.	3.3	26
11	A systematic analysis of UK cancer research funding by gender of primary investigator. BMJ Open, 2018, 8, e018625.	1.9	23
12	Systematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 1997-2010. Journal of Antimicrobial Chemotherapy, 2014, 69, 548-554.	3.0	21
13	Investments in cancer research awarded to UK institutions and the global burden of cancer 2000–2013: a systematic analysis. BMJ Open, 2017, 7, e013936.	1.9	20
14	Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997–2010. BMJ Open, 2014, 4, e004129.	1.9	19
15	Investments in respiratory infectious disease research 1997–2010: a systematic analysis of UK funding. BMJ Open, 2014, 4, e004600.	1.9	16
16	Infectious disease research investments follow colonial ties: questionable ethics. International Health, 2014, 6, 74-76.	2.0	14
17	Mapping pneumonia research: A systematic analysis of UK investments and published outputs 1997–2013. EBioMedicine, 2015, 2, 1193-1199.	6.1	14
18	Funding Infectious Disease Research: A Systematic Analysis of UK Research Investments by Funders 1997–2010, PLoS ONE, 2014, 9, e105722.	2.5	13

MICHAEL G HEAD

#	Article	IF	CITATIONS
19	Comparing research investment to United Kingdom institutions and published outputs for tuberculosis, HIV and malaria: a systematic analysis across 1997–2013. Health Research Policy and Systems, 2015, 13, 63.	2.8	11
20	Researching Scabies Outbreaks among People in Residential Care and Lacking Capacity to Consent: A Case Study. Public Health Ethics, 2017, 10, 90-95.	1.0	11
21	Precision public health to inhibit the contagion of disease and move toward a future in which microbes spread health. BMC Infectious Diseases, 2019, 19, 120.	2.9	11
22	Funding healthcare-associated infection research: a systematic analysis of UK research investments, 1997–2010. Journal of Hospital Infection, 2014, 87, 84-91.	2.9	10
23	Neonatal infection: a major burden with minimal funding. The Lancet Clobal Health, 2015, 3, e669-e670.	6.3	10
24	Allocation of funding into blast injury-related research and blast traumatic brain injury between 2000 and 2019: analysis of global investments from public and philanthropic funders. BMJ Military Health, 2023, 169, 127-132.	0.9	10
25	Investment in pneumonia and pneumococcal research. Lancet Infectious Diseases, The, 2014, 14, 1037-1038.	9.1	9
26	Scabies control: the forgotten role of personal hygiene – Authors' reply. Lancet Infectious Diseases, The, 2018, 18, 1068-1069.	9.1	9
27	Ivermectin for the control of scabies outbreaks in the UK. Lancet, The, 2019, 394, 2068-2069.	13.7	7
28	Systematic analysis of funding awarded for norovirus research to institutions in the United Kingdom, 1997–2010. Journal of the Royal Society of Medicine, 2014, 107, 110-115.	2.0	6
29	Rationale, experience and ethical considerations underpinning integrated actions to further global goals for health and land biodiversity in Papua New Guinea. Sustainability Science, 2020, 15, 1653-1664.	4.9	6
30	Are we investing wisely? A systematic analysis of nationally funded antimicrobial resistance projects in Republic of Korea, 2003–2013. Journal of Global Antimicrobial Resistance, 2016, 6, 90-94.	2.2	5
31	Monitoring investments in coronavirus research and development. Lancet Microbe, The, 2020, 1, e61.	7.3	5
32	Long-term consequences of the misuse of ivermectin data. Lancet Infectious Diseases, The, 2021, 21, 1624-1626.	9.1	5
33	Gross underinvestment in antibacterial research. Lancet Infectious Diseases, The, 2014, 14, 788-789.	9.1	4
34	Mapping Investments and Published Outputs in Norovirus Research: A Systematic Analysis of Research Funded in the United States and United Kingdom During 1997–2013. Journal of Infectious Diseases, 2016, 213, S3-S7.	4.0	4
35	Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope. Npj Vaccines, 2017, 2, 6.	6.0	4
36	Pneumonia in Ghanaâ \in "a need to raise the profile. International Health, 2018, 10, 4-7.	2.0	4

MICHAEL G HEAD

#	Article	IF	CITATIONS
37	A real-time policy dashboard can aid global transparency in the response to coronavirus disease 2019. International Health, 2020, 12, 373-374.	2.0	4
38	The Allocation of US\$ 105 Billion in Global Funding for Infectious Disease Research between 2000 and 2017: An Analysis of Investments from Funders in the G20 Countries. SSRN Electronic Journal, 0, , .	0.4	4
39	Infectious diseases amidst a humanitarian crisis in Ukraine: A rising concern. Annals of Medicine and Surgery, 2022, 78, .	1.1	4
40	Infectious disease research investments: Systematic analysis of immunology and vaccine research funding in the UK. Vaccine, 2013, 31, 5930-5933.	3.8	3
41	Systematic analysis of funding awarded for viral hepatitisâ€related research to institutions in the <scp>U</scp> nited <scp>K</scp> ingdom, 1997–2010. Journal of Viral Hepatitis, 2015, 22, 230-237.	2.0	3
42	Investments in sexually transmitted infection research, 1997–2013: a systematic analysis of funding awarded to UK institutions. Journal of Global Health, 2015, 5, 020405.	2.7	3
43	Networking for infectious disease. Nature Reviews Microbiology, 2008, 6, 328-328.	28.6	2
44	Global health priorities and research funding – Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 653.	9.1	2
45	Investing in sepsis research: systematic analysis of UK public and philanthropic funding 1997–2010. JRSM Open, 2014, 5, 205427041453895.	0.5	2
46	Systematic analysis of funding awarded to institutions in the United Kingdom for infectious disease research, 1997–2010. JRSM Open, 2015, 6, 205427041557705.	0.5	2
47	Transparency and availability of data for cancer research. Lancet, The, 2016, 388, 866-867.	13.7	2
48	Norovirus in 2016—Emesis Aplenty but Clear Signs of Progress. Journal of Infectious Diseases, 2016, 213, S1-S2.	4.0	2
49	Informing pneumococcal conjugate vaccine policy in middle-income countries: The case of Malaysia. Vaccine, 2017, 35, 2288-2290.	3.8	2
50	Research investments for UK infectious disease research 1997–2013: A systematic analysis of awards to UK institutions alongside national burden of disease. Journal of Infection, 2018, 76, 11-19.	3.3	2
51	Highlighting the forgotten: Tuberculosis amidst the humanitarian crisis and COVID-19 in Afghanistan. Annals of Medicine and Surgery, 2022, 77, 103671.	1.1	2
52	Infectious Disease Research Network. Journal of Antimicrobial Chemotherapy, 2009, 64, i25-i27.	3.0	1
53	Sex discrepancies in infectious disease research funding 1997–2010: a systematic analysis. Lancet, The, 2013, 382, S44.	13.7	1
54	The need for more investment in tuberculosis research. The Lancet Global Health, 2013, 1, e186.	6.3	1

MICHAEL G HEAD

#	Article	IF	CITATIONS
55	Global health priorities and research funding. Lancet Infectious Diseases, The, 2013, 13, 653.	9.1	1

56 Investing in antimicrobial resistance research. British Journal of Hospital Medicine (London, England:) Tj ETQq0 0 0 ggBT /Overlock 10 Tf

57	Can outbreak research be achieved in a population with impaired capacity? Findings from a study of a scabies outbreak in residential care. Lancet, The, 2015, 386, S48.	13.7	1
58	Challenges in mapping research investments for treatments against pneumonia. Lancet Infectious Diseases, The, 2015, 15, 1262.	9.1	1
59	Health service needs and perspectives of remote forest communities in Papua New Guinea: study protocol for combined clinical and rapid anthropological assessments with parallel treatment of urgent cases. BMJ Open, 2020, 10, e041784.	1.9	1
60	Lessons from the field: COVID-19 outbreak investigations in Kpone-Katamanso, Greater Accra, Ghana: a Global South approach to disease control and contact tracing. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 881-883.	1.8	1
61	The hub of the matter. Nursing Standard (Royal College of Nursing (Great Britain): 1987), 2010, 25, 64-64.	0.1	0
62	Funding infectious disease research: A systematic analysis of UK investments by funders 1997-2010. International Journal of Infectious Diseases, 2014, 21, 396.	3.3	0
63	The activity of the Research Investments in Global Health study and ways forward within the global funding and policy landscape. BMC Proceedings, 2016, 10, 59.	1.6	0
64	Databases for Research and Development. Emerging Infectious Diseases, 2019, 25, 1996-1996.	4.3	0
65	Reply: Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence. Npj Vaccines, 2020, 5, 56.	6.0	0
66	Proactive investment for virus research. Nature, 2022, 603, 228-228.	27.8	0